AbbVie's HUMIRA(R) (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
NORTH CHICAGO, Ill., Nov. 14, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has gr... Biopharmaceuticals, Dermatology, Regulatory AbbVie, HUMIRA, adalimumab, hidradenitis suppurativa (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 14, 2016 Category: Pharmaceuticals Source Type: news
Adalimumab for the Treatment of Hidradenitis Suppurativa Adalimumab for the Treatment of Hidradenitis Suppurativa
Hidradenitis suppurativa is a severe and chronic auto-inflammatory disease, with few therapeutic options, but recent Phase III clinical trials on the efficacy of adalimumab show promise.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 26, 2016 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Humira Partially Effective Against Hidradenitis Suppurativa Humira Partially Effective Against Hidradenitis Suppurativa
The anti-inflammatory drug adalimumab can provide significant relief for about a quarter of people who suffer from a moderate-to-severe case of the chronic skin condition hidradenitis suppurativa, according to two 36-week trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 4, 2016 Category: Consumer Health News Tags: Dermatology News Source Type: news
Clinical trial results support adalimumab treatment for painful skin condition
The results of two phase 3 clinical trials that led to FDA approval of adalimumab for treatment of the chronic inflammatory skin disease hidradenitis suppurtiva are now being published. An inhibitor of the inflammatory protein tumor necrosis factor, adalimumab is the first such medication approved to treat the painful skin disorder. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 4, 2016 Category: Science Source Type: news
Studies highlight diagnostic and treatment challenges in hidradenitis suppurativa
SCOTTSDALE, ARIZ. – Patients with hidradenitis suppurativa (HS) may be misdiagnosed when they see providers who are not dermatologists – as is usually the case during the initial years of their disease, according to a large analysis of medical claims data.
The findings highlight the need for... (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 3, 2016 Category: Dermatology Source Type: news
Hidradenitis suppurativa and diet: What's recommended?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - July 5, 2016 Category: Consumer Health News Source Type: news
Thousands are too embarrassed about boils to seek help
Hidradenitis suppurativa, or HS, affects three times as many women as men. Lorraine McPhail, 34, from Cumbernauld, North Lanarkshire, suffers from it. (Source: the Mail online | Health)
Source: the Mail online | Health - May 10, 2016 Category: Consumer Health News Source Type: news
UK NICE recommends Humira as treatment for hidradenitis suppurativa
The National Institute for Health and Care Excellence (NICE) has recommended the use of biopharmaceutical company AbbVie's Humira (adalimumab) for treatment of hidradenitis suppurativa (HS) in adults. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 8, 2016 Category: Pharmaceuticals Source Type: news
Risk of IBD doubled in hidradenitis suppurativa
WASHINGTON – Patients with hidradenitis suppurativa (HS) face an increased risk of also developing inflammatory bowel disease (IBD), Ahuva Cices said at the annual meeting of the American Academy of... (Source: Family Practice News)
Source: Family Practice News - April 4, 2016 Category: Primary Care Source Type: news
Uncontrolled hidradenitis suppurativa costs the health care system
WASHINGTON – One in four hidradenitis suppurativa patients saw their disease become more severe, requiring significantly more health care resources and driving up health care spending.
Dr. Alexa Boer Kimball, professor of dermatology at Harvard Medical School, Boston, and her colleagues reviewed... (Source: Skin and Allergy News)
Source: Skin and Allergy News - March 5, 2016 Category: Dermatology Source Type: news
Hidradenitis Suppurativa Tied to Higher MortalityHidradenitis Suppurativa Tied to Higher Mortality
Hidradenitis suppurativa (HS) is associated with a significantly increased risk of adverse cardiovascular (CV) outcomes and all-cause mortality, according to Danish researchers. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 25, 2016 Category: Dermatology Tags: Family Medicine/Primary Care News Source Type: news
Hidradenitis Suppurativa Linked With CV Risks (CME/CE)
(MedPage Today) -- Risks increased for MI, stroke, and cardiovascular death (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - February 17, 2016 Category: Consumer Health News Source Type: news
